Indium-111 bleomycin tumor scanning in lymphoma

Area of Science:

• Nuclear Medicine
• Oncology
• Radiopharmacology

Background:

• Lymphoma diagnosis and staging require accurate imaging techniques.
• Existing methods may have limitations in detecting all sites of disease involvement.

Purpose of the Study:

• To evaluate indium-111 labeled bleomycin (IB) as a tumor-imaging agent for lymphoma.
• To determine the accuracy of IB scanning for initial staging and serial evaluation of lymphoma patients.

Main Methods:

• Whole-body scans were performed 48 hours after intravenous administration of IB in 55 lymphoma patients.
• 731 individual sites of potential tumor involvement were assessed for accuracy.
• Serial scans were conducted in 19 patients to monitor disease status changes.

Main Results:

• Overall disease activity was correctly identified in 79% of scans.
• Lymphatic and soft tissue involvement were readily detected; bone marrow and hepatic involvement were less detectable.
• Scanning accuracy showed 90% true positives, 10% false negatives, 4% false positives, and 96% true negatives.
• Serial scans accurately reflected changes in disease status in 19 patients.

Conclusions:

• Indium-111 labeled bleomycin (IB) is a valuable new technique for lymphoma imaging.
• IB scanning facilitates initial staging and serial evaluation of patients with lymphoma.
• Further investigation may be needed for optimal detection of bone marrow and hepatic involvement.